Transcriptional silencing of -globin by BCL11A involves long-range interactions and cooperation with SOX6
Transcriptional silencing of γ-globin by BCL11A involves long-range interactions and cooperation with SOX6

Jian Xu, Vijay G. Sankaran, Min Ni, et al.

Genes Dev. 2010 24: 783-798
Access the most recent version at doi:10.1101/gad.1897310

Supplemental Material http://genesdev.cshlp.org/content/suppl/2010/04/12/24.8.783.DC1.html

References This article cites 68 articles, 35 of which can be accessed free at: http://genesdev.cshlp.org/content/24/8/783.full.html#ref-list-1

Open Access Freely available online through the Genes & Development Open Access option.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.
Transcriptional silencing of $\gamma$-globin by BCL11A involves long-range interactions and cooperation with SOX6

Jian Xu,1,2,3 Vijay G. Sankaran,1,2,4 Min Ni,5 Tobias F. Menne,1,2 Rishi V. Puram,4 Woojin Kim,1,2 and Stuart H. Orkin1,2,3,6

1Division of Hematology/Oncology, Children's Hospital Boston, Boston, Massachusetts 02115, USA; 2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA; 3Howard Hughes Medical Institute, Boston, Massachusetts 02115, USA; 4Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts 02115, USA; 5Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA

The developmental switch from human fetal ($\gamma$) to adult ($\beta$) hemoglobin represents a clinically important example of developmental gene regulation. The transcription factor BCL11A is a central mediator of $\gamma$-globin silencing and hemoglobin switching. Here we determine chromatin occupancy of BCL11A at the human $\beta$-globin locus and other genomic regions in vivo by high-resolution chromatin immunoprecipitation (ChIP)–chip analysis. BCL11A binds the upstream locus control region (LCR), $\gamma$-globin, and the intergenic regions between $\gamma$-globin and $\delta$-globin genes. A chromosome conformation capture (3C) assay shows that BCL11A reconfigures the $\beta$-globin cluster by modulating chromosomal loop formation. We also show that BCL11A and the HMG-box-containing transcription factor SOX6 interact physically and functionally during erythroid maturation. BCL11A and SOX6 co-occupy the human $\beta$-globin cluster along with GATA1, and cooperate in silencing $\gamma$-globin transcription in adult human erythroid progenitors. These findings collectively demonstrate that transcriptional silencing of $\gamma$-globin genes by BCL11A involves long-range interactions and cooperation with SOX6. Our findings provide insight into the mechanism of BCL11A action and new clues for the developmental gene regulatory programs that function at the $\beta$-globin locus.

[Keywords: Hemoglobin switching, fetal hemoglobin, BCL11A, transcription regulation]

Supplemental material is available at http://www.genesdev.org.

Received December 16, 2009; revised version accepted February 24, 2010.

The human $\beta$-globin locus on chromosome 11 contains the linked embryonic (e), fetal (G$\gamma$ and A$\gamma$), and adult (B$\delta$ and $\beta$) globin genes that are expressed sequentially during development. The $\beta$-globin locus provides a paradigm for tissue-specific and developmentally regulated transcription. Upstream of the locus lies a cluster of erythroid-specific cis-regulatory elements demarcated by DNase I-hypersensitive sites (HSs), known as the locus control region (LCR), which ensure high-level expression of the linked globin genes [Tuan et al. 1985; Forrester et al. 1986; Grosven\ldots\ldots; Bender et al. 2000]. Earlier studies using transgenic and knockout $\beta$-globin mouse models led to fundamental insight into the developmental regulation of gene expression and gene competition, and the function of distal transcriptional regulatory elements [Palstra et al. 2008]. Recently, the $\beta$-globin locus has provided the basis for studying long-range interactions mediated by inter- and intrachromosomal looping. For example, the LCR of the $\beta$-globin locus has been shown to be in close proximity to the active promoters, and also contacts other chromosomal regions in an erythroid cell and developmental stage-specific manner [Tolhuis et al. 2002; Palstra et al. 2003; Simonis et al. 2006; Schoenfelder et al. 2010].

The switch from human fetal ($\gamma$) to adult ($\beta$) expression is of particular interest due to its clinical importance. Delay of the switch or reactivation of fetal hemoglobin (HbF) in the adult stage greatly ameliorates clinical severity in the principal $\beta$-hemoglobin disorders sickle cell anemia and $\beta$-thalassemias. Over the last three decades, numerous approaches have been taken to elucidate the molecular events regulating normal human hemoglobin switching and the potential reactivation of HbF in adult hematopoietic cells [Stamatoyannopoulos...\ldots\ldots]
Various models—including gene silencing, gene competition, chromosomal looping, and tracking—have been presented for the fetal-to-adult globin switch (Orkin 1990; Stamatoyannopoulos 2005; Bank 2006). However, despite intensive molecular studies, the proteins regulating the switch and the mechanisms controlling the process have been largely elusive.

Recent human genetic studies focused on natural variation in the level of HbF expression in human populations shed new light on this complex regulatory process (Thein and Menzel 2009; Thein et al. 2009). More specifically, genome-wide association studies (GWAS) led to the identification of a new HbF-associated locus on chromosome 2, located within the gene BCL11A (Menzel et al. 2007; Thein et al. 2007; Lettre et al. 2008; Sedgwick et al. 2008; So et al. 2008; Uda et al. 2008; Thein and Menzel 2009). Subsequently, the gene BCL11A (also known as Evi9, Ctip1), encoding a zinc finger transcription factor, was shown to function as a regulator of HbF expression (Sankaran et al. 2008). Abundant expression of full-length forms of BCL11A is developmentally restricted to adult erythroid cells (Sankaran et al. 2008, 2009). Down-regulation of BCL11A expression in adult human erythroid precursors leads to robust induction of HbF (Sankaran et al. 2008). Knockout of BCL11A in transgenic mice harboring the human β-globin locus prevents proper silencing of endogenous mouse β-like embryonic genes and human γ-globin genes in adult erythroid cells of the fetal liver (Sankaran et al. 2009). Additionally, BCL11A interacts with the Mi-2/NuRD chromatin remodeling complexes, as well as the erythroid transcription factors GATA1 and FOG1, in erythroid progenitors [Sankaran et al. 2008]. These findings established BCL11A as the first genetically validated regulator of both developmental control of hemoglobin switching and silencing of γ-globin expression in adults.

SOX6 is a member of the Sry-related high-mobility group (HMG) box transcription factors, many of which serve as determinants of cell fate and differentiation in various lineages [Wegner 1999; Schepers et al. 2002]. A potential role for SOX6 in globin gene regulation was first recognized by analysis of the Sox6-deficient mouse. At the fetal liver stage, expression of mouse embryonic β-like globins [γy and β1] was dramatically elevated in the Sox6-deficient p100H mouse (Yi et al. 2006). While β1 was down-regulated rapidly in late fetal livers, the cyglobin gene was expressed persistently until birth (Yi et al. 2006). SOX6 also represses cy-globin and, to a lesser extent, β1-globin expression in definitive erythropoiesis of adult mice, as revealed by transplantation of fetal liver cells from Sox6-deficient mice into wild-type adult mice (Cohen-Barak et al. 2007). SOX6 acts as a repressor of cy-globin expression by direct binding to the cy promoter (Yi et al. 2006). SOX6 has also been suggested to enhance definitive erythropoiesis in mice by stimulating erythroid cell survival, proliferation, and terminal maturation (Dumitriu et al. 2006). A role for SOX6 in human globin gene regulation has not yet been examined directly, although recent work in human erythroid progenitors suggests that variation in the levels of SOX6 correlates with γ-globin gene expression (Sripichai et al. 2009).

While a precise role for SOX6 in hemoglobin switching remains to be determined, SOX6 appears to act as either an activator or a repressor, depending on its interacting proteins and promoter context [Lelehrve et al. 1998; Murakami et al. 2001]. In addition, Sox transcription factors bind to the minor groove of DNA and cause a drastic bend of the DNA that leads to local conformational changes [Ferrari et al. 1992; Connor et al. 1994]. Therefore, it has been suggested that SOX6 may perform part of its function as an architectural factor by organizing local chromatin structure and assembling other DNA-bound transcriptional factors into biologically active, sterically defined multiprotein transcriptional complexes (Yi et al. 2006).

Here we show that full-length BCL11A protein occupies the β-globin locus in vivo in primary adult human erythroid cells. BCL11A associates with distal regulatory elements and reconfigures the β-globin cluster. We show that SOX6 is also required to maintain silencing of human γ-globin genes in definitive erythropoiesis. BCL11A and SOX6 are coexpressed, interact physically, co-occupy the human β-globin cluster, and act collaboratively in silencing γ-globin transcription in adult human erythroid cells. Our findings provide important insights into the developmental gene regulatory programs operating at the human β-globin locus, and new clues for manipulating globin gene expression as an approach to treat human blood diseases.

**Results**

**BCL11A occupies the human β-globin cluster in vivo**

The identification of BCL11A as a critical switching factor allows focused mechanistic studies to dissect the globin switching process. In principle, BCL11A might silence γ-globin expression either directly by interacting with cis-regulatory elements within the β-globin cluster, or indirectly by affecting other pathways that ultimately impact γ-globin transcription. To investigate whether BCL11A silences γ-globin expression by direct association with the human β-globin locus, we previously used chromatin immunoprecipitation (ChIP) followed by quantitative PCR to examine in vivo binding of BCL11A protein to the β-globin locus in adult human erythroid progenitors [Sankaran et al. 2008]. The results indicated that BCL11A occupies several discrete regions within the human β-globin cluster. These include the third HS (HS3) of the LCR and an intergenic region between Aγ-globin and δ-globin genes [Sankaran et al. 2008]. Such results argue that BCL11A acts within the β-globin locus. A fuller accounting of the mechanism necessitates comprehensive analysis of chromatin occupancy of BCL11A and its partner proteins in the β-globin cluster.

To obtain high-resolution chromatin occupancy of BCL11A in the β-globin locus and other genomic regions, we performed ChIP-chip analysis in primary adult human erythroid progenitors. We used the human ENCODE
2.0R array, which is comprised of 30 Mb of DNA or ~1% of the human genome. The ENCODE array encompasses the entire human β-globin cluster and offers exceptionally high resolution [7-base-pair (bp) tiling] in the most detailed genomic view [The ENCODE Project Consortium 2004]. BCL11A has at least four alternatively spliced isoforms [Supplemental Fig. 1A]. We previously described that BCL11A is expressed as short variant proteins at stages that robustly expressed the γ-globin genes [primitive and fetal liver erythroid progenitors], but not in adult erythroid cells in which γ-globin genes are silenced (Sankaran et al. 2008, 2009). These short variants, however, do not correspond to reported BCL11A isoforms, and their identities remain unknown. In primary adult human erythroid cells, BCL11A is expressed as two major isoforms [designated XL and L] at both the protein and RNA levels [Supplemental Fig. 1; Sankaran et al. 2008, 2009]. These isoforms differ only in usage of the 3′- terminal exon and function similarly in other settings (Liu et al. 2006). At the protein level, the XL and L isoforms are indistinguishable due to their similar size (Sankaran et al. 2008). At the mRNA level, the XL isoform is seven times more abundant than the L isoform in adult human erythroid progenitors and appears at a similar ratio in mouse erythroid cells [Supplemental Fig. 1B,C]. To assess chromatin occupancy of both XL and L isoforms more comprehensively than before, we used three different antibodies directed to BCL11A in ChIP–chip experiments [Supplemental Fig. 1A]. The a1b and ab2 antibodies react with both XL and L isoforms, while the ab3 antibody reacts only with the XL isoform. The high-resolution mapping of chromatin occupancy using three antibodies reveals that BCL11A associates with the β-globin locus in vivo. As shown by the peaks, very similar patterns of BCL11A occupancy at the β-globin cluster were observed using all three antibodies [Fig. 1A]. These data suggest that the XL isoform is the predominant form present in human erythroid progenitors and occupies discrete chromatin regions within the β-globin locus in vivo. Collectively, BCL11A binds strongly to the upstream HSs within the LCR, the embryonic ε-globin, and the intergenic region between Aγ-globin and δ-globin [Fig. 1A].

The binding peaks within the δγ-intergenic region overlap previously reported deletion mutations in humans associated with elevated HbF expression [Bank 2006]. Importantly, BCL11A does not detectably bind to the promoter regions of the γ-globin genes, suggesting that BCL11A may perform its function through long-distance interactions within the β-globin locus.

Genome-wide analysis of BCL11A ChIP–chip data sets generated with the three antibodies reveals a significant number of shared sites [Fig. 1B]. Out of 267 BCL11A sites, 204 (76.4%) were present in at least two data sets [Fig. 1B]. Genomic-scale analysis of the ChIP–chip signal [from a WIG file] (Shin et al. 2009) also shows a strong correlation and mutual enrichment among three data sets [Fig. 1C,E]. A motif search within sites enriched for BCL11A binding identified three de novo GC-rich motifs for BCL11A binding [Supplemental Fig. 2A]. We next examined the location of BCL11A-binding sites [all three data sets combined] relative to annotated gene structures based on the University of California at Santa Cruz Genome Browser Database [Karolchik et al. 2008]. Two percent of the peaks occur within proximal promoters [defined as ~3 kb to +1 kb relative to transcription start site], 2% lie within coding exons, 45% are within introns, 2% are located within the 5′ untranslated region (UTR) and 3′UTR [gene end], and 49% are intergenic [Fig. 1D]. These results suggest that BCL11A tends to associate with distal control regions, in contrast to other transcription factors [see below], in adult human erythroid cells.

**BCL11A-binding sites are devoid of common histone modifications**

To ascertain whether chromatin occupancy of BCL11A coincides with common histone modifications, ChIP–chip experiments were performed using antibodies directed to acetylated histone H3 Lys 9 [H3K9ac], dimethyl-H3 Lys 4 [H3K4me2], trimethyl-H3 Lys 4 [H3K4me3], and trimethyl-H3 Lys 27 [H3K27me3]. H3 acetylation and H3K4 methylation are associated with transcriptionally active or poised genes, while H3K27 methylation is generally associated with transcriptional repression (Li et al. 2007). Peaks of acetylated H3 and di- and trimethylated H3K4 are observed at the upstream LCR, the actively transcribed δ-globin and β-globin genes, and an intergenic region between Aγ-globin and δ-globin [Fig. 1A]. Weak peaks of active histone modifications are also observed at the largely inactive Gγ-globin and Aγ-globin genes. In contrast, peaks of trimethylated H3K27 are present only at the proximal promoters of the γ-globin genes, consistent with their very low-level expression in adult human erythroid cells. Importantly, high-resolution mapping of BCL11A binding and histone modifications reveals that BCL11A-binding sites are devoid of active histone modifications within the human β-globin locus [Fig. 1A]. Particularly, the peaks of BCL11A at the ε-globin region bear no detectable enrichment of acetylated H3 and methylated H3K4 or H3K27. The other two strong peaks of BCL11A located at the H53 site and the δγ-intergenic region are located in the “valley” of neighboring peaks for active histone modifications [H3K9ac, H3K4me2, and H3K4me3] [Fig. 1A]. Global analysis of cooccupancy between BCL11A, H3K4, and H3K27 trimethylation also reveals a lack of shared binding sites between BCL11A and common histone modifications at a genome scale [Fig. 1E, Supplemental Fig. 2B,C].

**BCL11A reconfigures the human β-globin locus**

The lack of detectable association of BCL11A with the proximal promoter regions of the γ-globin genes suggests that BCL11A does not act in transcriptional repression locally at these genes. As an alternative mode of action, BCL11A might silence γ-globin expression through binding to distal control regions and mediate long-distance interaction by reconfiguration of the β-globin cluster at different development stages. To test this hypothesis, we employed chromatin conformation capture (3C) assay to examine the structure of the human β-globin locus in the...
presence or absence of BCL11A in fetal liver cells from human β-YAC mice. In this experiment, mouse fetal liver cells derived from β-YAC mice with either wild-type (Bcl11a+/+) or Bcl11a-null (Bcl11a−/−) alleles were examined (Fig. 2). Since these adult-type erythroid cells contain the human β-globin locus, we can assess chromatin structure in the presence or absence of BCL11A. In the 3C method, distances between a predefined “anchor region” and other positions in the locus are measured through a ligation assay. If the anchor region interacts physically with a downstream region, the relative cross-linking efficiency between those two regions will be higher than other regions lacking contact.

In mice wild type for BCL11A, the anchor region at the LCR has the highest cross-linking efficiency with the β-globin gene, indicating loop formation (Fig. 2A). The two γ-genes are cross-linked much less efficiently, indicating that the LCR regions interact preferentially with the adult genes in the presence of BCL11A. This observation is consistent with the predominant expression of β-gene at this stage (Supplemental Fig. 3; Sankaran et al. 2009). In contrast, in Bcl11a−/− cells, the locus is
reconfigured such that the \(\gamma\)-genes are highly associated with the LCR, while the \(\beta\)-gene is cross-linked less efficiently [Fig. 2A]. This finding, again, is consistent with the observation that \(\gamma\)-globins are the predominant subtypes expressed in these cells (Supplemental Fig. 3; Sankaran et al. 2009), indicating that the LCR regions strongly favor the interaction with the fetal genes in the absence of BCL11A. Similarly, use of the 3'HS1 as the anchor region reveals that the \(\gamma\)-genes are cross-linked at much higher efficiency in the absence of BCL11A [Fig. 2B]. These results strongly support the hypothesis that BCL11A performs part of its function by reconfiguring the \(\beta\)-globin locus.

**BCL11A and SOX6 are coexpressed during erythroid development**

The study of human hemoglobin switching has relied largely on transgenic mouse models, such as human \(\beta\)-locus mice, or on in vitro culture systems that employ various cytokines to induce erythroid maturation of purified primary hematopoietic progenitors or pluripotent embryonic stem (ES)-like cells (Strouboulis et al. 1992; Gaensler et al. 1993; Peterson et al. 1993; Migliaccio et al. 2002). Although the transgenic mouse model provides a valid system for evaluating human developmental globin regulation, key limitations have been noted. Mice have no fetal globin equivalent and the human fetal (\(\gamma\)) globin genes behave largely as embryonic globin genes in these mice, demonstrating that critical differences in the trans-acting milieu have arisen during mammalian evolution (Sankaran et al. 2009). To circumvent these issues, we employed a serum-free two-phase liquid culture system to generate highly enriched populations of maturing, primary erythroblasts ex vivo from purified CD34\(^+\) human hematopoietic progenitors (Sankaran et al. 2008). In this experimental context, maturing erythroid precursors recapitulate the normal sequence of maturation from proerythroblasts to orthochromatic erythroblasts [Fig. 3A]. By day 5 in culture medium that supports terminal erythroid maturation, the majority of cells acquire proerythroblast morphology. By day 7, cells exhibit basophilic erythroblast morphology. By days 9–12 of differentiation, the majority of cells are polychromatophilic and orthochromatophilic [Fig. 3A]. Surface marker expression during differentiation includes loss of CD45 antigen, reduced expression of CD45, and acquisition of transferrin receptor (CD71), glycophorin A (CD235a), and antigen CD36 (Supplemental Fig. 4). This ex vivo culture system results in robust expression of adult hemoglobin (\(\beta\)-globin) and low-level HbF (\(\gamma\)-globin) production [Fig. 3B; Supplemental Fig. 5].

Because BCL11A does not reside at the promoters of the \(\gamma\)-genes [Fig. 1A], it is likely that other factors cooperate with BCL11A to achieve their proper silencing within the \(\beta\)-globin locus. SOX6 has been shown previously to silence the mouse embryonic \(\gamma\)-globin and \(\beta\)H1-globin expression, probably by direct association with the \(\gamma\) promoter (Yi et al. 2006). Given that the human \(\gamma\)-gene behaves as an embryonic gene in the mouse erythroid *trans*-acting environment (Sankaran et al. 2009), we hypothesized that SOX6 may also be involved in \(\gamma\)-gene control. As a first step in asking whether BCL11A and SOX6 might act together in globin gene regulation, we examined the expression of BCL11A and SOX6 in primary adult human erythroid cells. Both BCL11A (XL and L isoforms) and SOX6 are highly expressed during mid-maturation (days 5–7), corresponding to the proerythroblast and basophilic erythroblast stages [Fig. 3C; Supplemental Fig. 6]. Expression of both proteins was much reduced in CD34\(^+\) hematopoietic

---

**Figure 2.** BCL11A reconfigures the human \(\beta\)-globin cluster. Locus-wide cross-linking frequencies show reconfiguration of the human \(\beta\)-globin cluster in the absence of Bcl11a. Relative cross-linking frequencies observed in wild-type [Bcl11a\(^{-/-}\)] E14.5 fetal liver erythroid cells are shown in blue, and Bcl11a\(^{-/-}\) cells are shown in red. Gray shading indicates position and size of the analyzed fragments, and black shading represents the “anchor region” HS2–HS4 (A) and 3’HS1 (B). Spatial organization of the human \(\beta\)-globin locus is indicated at the top. Schematic diagrams representing the three-dimensional interactions that occur within the human \(\beta\)-globin cluster are shown at the side. In each graph, the highest cross-linking frequency value was set to 1. The X-axis shows position (in kbp) in the locus. All data are plotted as the mean ± SD of the measurement.

---

**Figure 3.** (A) Surface marker expression during differentiation indicates loss of CD45 antigen, reduced expression of CD45, and acquisition of transferrin receptor (CD71), glycophorin A (CD235a), and antigen CD36 (Supplemental Fig. 4). (B) Ex vivo culture system results in robust expression of adult hemoglobin (\(\beta\)-globin) and low-level HbF (\(\gamma\)-globin) production (Fig. 3B; Supplemental Fig. 5). Because BCL11A does not reside at the promoters of the \(\gamma\)-genes (Fig. 1A), it is likely that other factors cooperate with BCL11A to achieve their proper silencing within the \(\beta\)-globin locus. SOX6 has been shown previously to silence the mouse embryonic \(\gamma\)-globin and \(\beta\)H1-globin expression, probably by direct association with the \(\gamma\) promoter (Yi et al. 2006). Given that the human \(\gamma\)-gene behaves as an embryonic gene in the mouse erythroid *trans*-acting environment (Sankaran et al. 2009), we hypothesized that SOX6 may also be involved in \(\gamma\)-gene control. As a first step in asking whether BCL11A and SOX6 might act together in globin gene regulation, we examined the expression of BCL11A and SOX6 in primary adult human erythroid cells. Both BCL11A (XL and L isoforms) and SOX6 are highly expressed during mid-maturation (days 5–7), corresponding to the proerythroblast and basophilic erythroblast stages (Fig. 3C; Supplemental Fig. 6). Expression of both proteins was much reduced in CD34\(^+\) hematopoietic
progenitors and in more mature erythroblasts. Similarly, mouse Bcl11a and Sox6 mRNAs are both highly expressed in stage II (Ter119^+/C0^+CD71^+), stage II (Ter119^+/CD71^hi) (Zhang et al. 2003) populations in mouse fetal liver (embryonic day 14.5 [E14.5]) cells (Fig. 3D–F). Thus, BCL11A and SOX6 are coexpressed during erythroid development in both humans and mice.

SOX6 comigrates and interacts physically with BCL11A

The coexpression of BCL11A and SOX6 during erythroid differentiation suggests that these factors, both of which have been described previously as mediators of hemoglobin switching and silencing of mouse embryonic globin gene expression (Yi et al. 2006; Sankaran et al. 2009), may function together in regulating globin switching in a protein complex. To explore this possibility, we first examined the migration of BCL11A and SOX6 in human erythroid nuclear extracts by gel filtration chromatography. As shown in Figure 4A, BCL11A migrates as a major peak centered between 440-kDa and 2-MDa markers. The BCL11A elution pattern overlaps substantially with the NuRD components MBD3, HDAC1, and HDAC2, suggesting that BCL11A strongly associates with NuRD complexes in human erythroid cells (Fig. 4A). A small proportion of SOX6 elutes in fractions corresponding to lower molecular mass (<440 kDa), indicating that SOX6 may also be present in association with other proteins.

The chromatographic profile demonstrates that SOX6, together with BCL11A and NuRD complexes, comigrates in vitro and are likely part of a multiprotein complex. To further explore the relationship of BCL11A and SOX6 proteins, we ectopically expressed V5-tagged SOX6 with Flag-tagged BCL11A (XL isoform), GATA1, or MBD3 in COS7 cells, followed by coimmunoprecipitation (co-IP). Both BCL11A and GATA1 efficiently coimmunoprecipitate SOX6, indicating that SOX6 interacts physically with BCL11A and GATA1 (Fig. 4B; Supplemental Fig. 7). NuRD components MBD3 and MTA2 are unable to interact with SOX6, suggesting that SOX6 makes independent contact with BCL11A (Fig. 4B; Supplemental Fig. 7). Furthermore, in human erythroid cell nuclear extracts, α-BCL11A antibody efficiently immunoprecipitates endogenous SOX6 and GATA1 proteins (Fig. 4C). Similarly, α-SOX6 antibody efficiently immunoprecipitates endogenous BCL11A and GATA1 proteins (Fig. 4D). These data demonstrate that SOX6 interacts directly with BCL11A and GATA1 under physiological conditions in human erythroid progenitors.

To further characterize the determinants mediating association between BCL11A, SOX6, GATA1, and other protein partners, we mapped the interaction domains by co-IP assays of epitope-tagged proteins expressed transiently in COS7 cells (Fig. 4E–G). As shown in Figure 4A, BCL11A migrates as a major peak centered between 440-kDa and 2-MDa markers. The BCL11A elution pattern overlaps substantially with the NuRD components MBD3, HDAC1, and HDAC2, suggesting that BCL11A strongly associates with NuRD complexes in human erythroid cells, similar to prior observations in mouse erythroleukemia (MEL) cells and B lymphoid cells (Cismasiu et al. 2005; Sankaran et al. 2008). Importantly, SOX6 also comigrates predominantly with BCL11A and NuRD components (Fig. 4A). A small proportion of SOX6 elutes in fractions corresponding to lower molecular mass (<440 kDa), indicating that SOX6 may also be present in association with other proteins.

**Figure 3.** BCL11A and SOX6 are coexpressed during erythroid development. (A) Human CD34+ cells were induced for erythroid differentiation in a serum-free two-phase liquid culture model. Representative cytospin images were shown for undifferentiated CD34+ cells, proerythroblasts [Pro-E], basophilic erythroblasts [Baso-E], polychromatic erythroblasts [Poly-E], and orthochromatic erythroblasts [Ortho-E]. (B) Globin mRNA levels were monitored by real-time RT–PCR in erythroid cells at various differentiation stages. All transcript levels were normalized against human GAPDH transcript levels. (C) The expression of human BCL11A and SOX6 proteins was measured by Western blot. GAPDH was analyzed as a loading control. (D) The CD71 and Ter119 expression pattern is shown for mouse fetal liver cells from E14.5 embryos. The cells were FAC-sorted into four populations (I, II, III, and IV) as described previously (Zhang et al. 2003). (E, F) Mouse Bcl11a and Sox6 mRNA levels were measured by real-time RT–PCR. Transcript levels were normalized against mouse Gapd transcript levels. All results are means ± SD of at least three independent experiments.
through multiple domains, likely through multiple zinc fingers, similar to the interactions between GATA1 and FOG1 (Cantor and Orkin 2005). Interestingly, the three C-terminal zinc fingers (732–835 amino acids) are unable to interact with GATA1, GATA2, and FOG1 (Fig. 4C), suggesting that SOX6 makes independent contacts with BCL11A. The N-terminal 12 amino acids are highly homologous among BCL11A, BCL11B, FOG1, FOG2, and SALL1–4 proteins, and serve as a transcriptional repression motif that mediates interaction with the Mi-2/NuRD nucleosomal remodeling complexes (Lin et al. 2004). Nevertheless, our results demonstrate that the N-terminal
90 amino acids are necessary and sufficient for interaction of BCL11A with the NuRD component MTA2 (Fig. 4G).

**BCL11A, SOX6, and GATA1 co-occupy the human β-globin cluster**

We next examined the in vivo chromatin occupancy of BCL11A and SOX6 at the β-globin cluster in primary human erythroid progenitors by ChIP–chip. The alignment of BCL11A and SOX6 ChIP–chip peaks reveals partial overlap, particularly at the HS3 site of the upstream LCR and the embryonic ε-globin gene [Fig. 5A; Supplemental Fig. 8]. Importantly, SOX6 strongly binds the Ay and Gy proximal promoters, reminiscent of the role of SOX6 in silencing mouse εy-globin expression by association with its proximal promoter [Yi et al. 2006]. In contrast, BCL11A does not detectably bind to γ-promoters by ChIP–chip [Figs. 1A, 5A]. Given the observation that these two proteins physically interact and likely associate within a protein complex (or complexes), these results suggest that SOX6 may act as a partner of BCL11A in silencing γ-globin expression. These data also suggest

---

**Figure 5.** Chromatin occupancy of BCL11A, SOX6, and GATA1 within the human β-globin locus in adult human erythroid progenitors. [A] In vivo chromatin occupancy of BCL11A, SOX6, GATA1, and RNA Pol II was examined by ChIP–chip in human erythroid progenitors. Precipitated DNA samples were amplified and hybridized to human ENCODE 2.0R array. A genome browser representation of binding patterns at the human β-globin cluster is shown. Relative positions of the human β-like globin genes and the upstream LCR consisting of five DNase I HSs (1–5) are shown at the bottom. [B] A Venn diagram of genome-wide colocalization of BCL11A, SOX6, and GATA1 ChIP–chip sites is shown. [C] Genome-wide analysis of BCL11A, SOX6, and GATA1 cooccupancy is shown. Scatter plots display mutual enrichment between indicated ChIP–chip data sets relative to the input. Correlation values are shown. [D] Sitepro (Shin et al. 2009) analysis of genome-wide correlation between the indicated ChIP–chip data sets. The average signal (from a WIG) is shown for a 2-kb region surrounding the center of ChIP–chip sites from the BCL11A.ab1 data set. [E] Distribution of SOX6 and GATA1 enrichment peaks located in the promoter (−3 kb to +1 kb), coding exon, intron, gene end (5’UTR and 3’UTR), or intergenic enhancers (outside of these defined regions) is shown. [F] In vivo chromatin occupancy of SOX6, GATA1, and RNA Pol II was examined by ChIP in E14.5 fetal liver cells from β-YAC control mice (Bcl11a+/+) and Bcl11a-null mice (Bcl11a−/−). Precipitated DNA samples were quantified using primers designed to amplify several control regions within the human β-globin locus as indicated below each graph. The ChIP signals are shown as a percentage of the input DNA signal. Results are mean ± SD of three independent experiments. [G] Relative mRNA expression of SOX6 was examined by real-time RT–PCR in FACS-sorted Ter119+CD71+ E14.5 fetal liver erythroid cells from Bcl11a+/+ (wild-type, n = 3) and Bcl11a−/− (n = 3) embryos. Transcript levels were normalized against mouse Gapd transcript levels. Results are means ± SD.
that SOX6, by interacting with γ-proximal promoters, may help recruit BCL11A to the proximal regions of the γ-genes during hemoglobin switching.

To obtain insight into whether other BCL11A-interacting partners are also recruited to the same chromatin regions in vivo, we mapped the binding of GATA1 across the β-globin cluster by ChIP-chip. The results indicate strong association of GATA1 with the upstream HS1, HS3, HS4, and HS5 within the LCR region, and the intergenic regions between the Aγ-genes and δ-genes (Fig. 5A; Supplemental Fig. 8). The binding peaks of GATA1 at the β-globin cluster overlap substantially with those of SOX6 and partially with peaks of BCL11A, suggesting that these proteins may function in a chromatin-associated multiprotein complex (or complexes) within the β-globin locus. The presence of BCL11A, SOX6, and GATA1 at the HS3 site within the LCR is consistent with a potential role of HS3 in mediating γ-globin transcription [Navas et al. 1998; Fang et al. 2005], likely through rearrangement of the configuration of the β-globin cluster by long-range interactions [Fig. 2A]. In addition, RNA polymerase II (Pol II) is strongly associated with the LCR HS1, HS3, and HS4 sites, and the δ and β promoters. The strong binding of Pol II at the promoters of δ-globin and β-globin genes is consistent with their active transcription in adult erythroblasts [Figs. 3B, 5A].

Global analysis of BCL11A, SOX6, and GATA1 ChIP-chip data sets also reveals a significant number of shared sites [Fig. 5B] and mutual enrichment [Fig. 5C,D] at the genomic scale. Of the BCL11A sites, 28.7% (31 out of 108) and 24.1% (26 out of 108) are shared by SOX6 and GATA1, respectively, and 17.6% (19 out of 108) are co-occupied by all three factors [Fig. 5B]. These include the HS3 site and δ-globin promoter at the β-globin locus [Fig. 5A]; Genome-wide analysis of SOX6 and GATA1 distribution reveals a similar pattern [Fig. 5E]. In contrast to BCL11A [Fig. 1D], a significant number of GATA1- and SOX6-binding sites are located within proximal promoters at a genomic scale.

If BCL11A, SOX6, and GATA1 bind the human β-globin cluster and silence γ-globin expression in a functional protein complex [or complexes], ablation of one critical component of the complex might lead to destabilization of the larger complex and/or its chromatin occupancy. We next determined whether the binding of SOX6 and GATA1 to the β-globin locus is dependent on the presence of BCL11A. ChIP was performed using mouse fetal liver cells derived from β-YAC mice with either wild-type or Bcl11a-null alleles. Since these adult-type erythroid cells contain the human β-globin locus, we can assess chromatin association of SOX6 in the presence or absence of BCL11A. In fetal liver cells wild-type for BCL11A, binding of SOX6 is enriched significantly at the Aγ promoter and the +3-kb downstream regions [Fig. 5F, Bcl11a+/−], similar to the pattern observed in the human erythroid cells [Fig. 5A, Supplemental Fig. 8]. In Bcl11a-null cells, binding of SOX6 to the Aγ promoter region is decreased by 5.5-fold. The binding of SOX6 to other control regions within the β-globin locus is also decreased [Fig. 5F, Bcl11a−/−], indicating that loss of BCL11A leads to impaired chromatin occupancy of SOX6 within the human β-globin locus. In addition, the expression of SOX6 is reduced by 55% in the Bcl11a-null fetal liver erythroid cells as compared with the wild-type controls [Fig. 5G], suggesting that the reduced SOX6 chromatin occupancy may be due in part to the down-regulation of SOX6 expression in the absence of BCL11A. Interestingly, loss of BCL11A leads to increased GATA1 and RNA Pol II occupancy at the Aγ promoter, the γδ-intergenic regions [Aγ + 3 kb], and the 3′HS1 site. The enhanced Pol II occupancy at the Aγ promoter region is consistent with transcriptional reactivation of the γ-globin genes in the Bcl11a-null fetal liver cells [Supplemental Fig. 3; Sankaran et al. 2009]. Taken together, these results demonstrate that loss of BCL11A in fetal liver definitive cells leads to diminished SOX6 occupancy within the β-globin locus, accompanied by elevated GATA1 and Pol II occupancy at the γ-globin promoter regions.

SOX6 cooperates with BCL11A in silencing mouse embryonic globins

The observation that repression of the endogenous embryonic ε-globin and β1-globin genes is greatly impaired in definitive fetal liver erythrocytes of both Sox6 null mice and Bcl11a-null mice suggests that SOX6 and BCL11A may function collaboratively in their silencing [Yi et al. 2006; Sankaran et al. 2009]. To test this hypothesis, we used lentivirus-mediated shRNAs to knock down the expression of BCL11A and/or SOX6 in MEL cells. In MEL cells, the mouse adult β-globins [βmajor and βminor] are expressed abundantly, and the embryonic ε-globin and β1-globin are expressed at very low levels. MEL cells were transduced with control shRNA, BCL11A shRNA, or SOX6 shRNA lentiviruses, respectively. To knock down both BCL11A and SOX6 expression, MEL cells were transduced with SOX6 shRNA lentivirus [containing a puromycin-selectable cassette] and BCL11A shRNA lentivirus [containing a GFP cassette]. Puromycin selection was imposed 1 d after transduction followed by GFP FACS sorting during the day of analysis (usually 4 d after transduction). As shown in Figure 6A, transduction of shRNA lentiviruses led to strong knockdown of BCL11A and/or SOX6 proteins. To determine the consequences of gene knockout, we examined the mRNA expression of ε-globin, β1-globin, and βmajor/βminor-globins by quantitative RT-PCR [Fig. 6B]. Knockdown of BCL11A alone led to a 116-fold increase of ε-globin mRNA transcripts. Knockdown of SOX6 alone led to a modest increase [15-fold] of ε-globin mRNA. Similar effects on ε-globin expression were observed with two other SOX6 shRNA lentiviruses (data not shown). Strikingly, combined knockdown of BCL11A and SOX6 led to a substantial increase of ε-globin mRNA by 429-fold [Fig. 6B], indicating that SOX6 and BCL11A act together to maintain silencing of the ε-globin gene in MEL cells. Expression of β1-globin was also derepressed to a lesser extent upon knockdown of BCL11A and SOX6, while expression of βmajor/βminor-globins remained largely unaffected [Fig. 6B]. Taken together, these findings...
demonstrate that SOX6 cooperates with BCL11A to silence the expression of mouse embryonic β-like globin genes in MEL cells.

SOX6 contributes to the silencing of γ-globin expression in adult human erythroid cells

Because the human γ-globin genes are regulated largely as embryonic genes in the β-locus transgenic mouse, and SOX6 silences embryonic globin genes in mice, we hypothesized that SOX6 may be involved in γ-gene control. To assess a potential functional role for SOX6 in γ-globin expression, we employed shRNA knockdown in cultured primary adult human erythroid progenitors by lentivirus-mediated shRNAs as described previously [Moffat et al. 2006; Sankaran et al. 2008]. As controls, we also infected the cells with either BCL11A shRNA alone, SOX6 shRNA alone, or control shRNA. Similar to the shRNA knockdown experiment in MEL cells, we employed puromycin selection and GFP FACs sorting to select for cells transduced with both SOX6 and BCL11A shRNA lentiviruses. When cells were transduced with the BCL11A and/or SOX6 shRNA lentiviruses and selection was imposed on the initiation of differentiation, we obtained an average of 99% and 95% knockdown of BCL11A and SOX6 proteins, respectively, by day 5 of erythroid maturation [Fig. 6C]. No obvious morphological differences between the groups of cells were noted during differentiation, indicating that BCL11A knockdown and SOX6 knockdown do not impair differentiation of CD34+ cells into proerythroblasts [Supplemental Fig. 9; Sankaran et al. 2008]. Remarkably, the level of γ-globin mRNA at day 5 of maturation was elevated by 4.8-fold, 2.1-fold, and 6.6-fold (from an average of 6.7% in the control to 31.8%, 14.2%, and 43.9% in cells transduced with either BCL11A shRNA alone, SOX6 shRNA alone, or both shRNAs, respectively) [Fig. 6D]. Levels of mature HbF were also measured by hemoglobin electrophoresis [Fig. 6E]. In control cells, only 0.2% of total hemoglobin produced is HbF. Upon knockdown of BCL11A alone, we obtained 28.9% HbF. Knockdown of SOX6 alone led to modest induction of HbF to 4.7%. Combined knockdown of BCL11A and SOX6 led to a substantial increase in HbF [to >45%]. This level is greater than that observed upon knockdown of BCL11A, again suggesting that BCL11A and SOX6 act together to silence HbF expression. Quantification of HbF by high-performance liquid chromatography [HPLC] confirmed these observations [Supplemental

Figure 6. BCL11A cooperates with SOX6 in silencing γ-globin gene expression. (A) Lentivirus-mediated shRNA delivery to MEL cells results in robust knockdown of both BCL11A and SOX6 proteins. Control samples were transduced with lentivirus prepared from the shRNA empty vector. Cells were harvested 4 d after transduction and analyzed by Western blot using antibodies for SOX6 and BCL11A. β-Actin was analyzed as a loading control. (B) shRNA-mediated knockdown of BCL11A and SOX6 results in elevations of γy-globin and β1-globin mRNAs. *P < 0.001 (****) and **P < 0.01 (*) in comparison with controls. (C) Lentiviral shRNA in human erythroid progenitors results in robust knockdown of both BCL11A and SOX6 proteins. Control samples were transduced with lentivirus prepared from the empty vector. Cells were harvested 7 d after transduction, which usually corresponded to day 5 in differentiation medium. Whole-cell lysates were prepared and analyzed by Western blot using antibodies for SOX6 and BCL11A. β-Actin was analyzed as a loading control. An asterisk (*) indicates nonspecific bands. (D) shRNA-mediated knockdown of BCL11A and SOX6 results in elevations of γ-globin mRNA levels as a percentage of total β-like globin gene expression on day 5 of differentiation. **P < 0.001 (****) and ***P < 0.01 (*) in comparison with controls. (E) Hemolysates prepared from cells on day 14 of differentiation (terminal stage erythroblasts) show the presence of mature HbF. This was assessed using cellulose acetate hemoglobin electrophoresis with a size marker indicating the positions of HbA and HbF. The percentages indicating the proportion of hemoglobin species were determined by measurement from densitometry. All results are means ± SD from three independent experiments. Statistical significance was calculated using a Student t-test.
Fig. 10). Taken together, these results argue persuasively that BCL11A cooperates with SOX6 to silence γ-globin expression in adult human erythroid cells.

Discussion

Here we determined and analyzed the genome-wide occupancy of BCL11A in primary adult human erythroid cells using ChIP followed by hybridization to the human ENCODE array. The exceedingly high 7-bp resolution of the ENCODE array allows fine mapping of BCL11A-binding sites within the human β-globin locus, as well as other genomic regions. The high-resolution ChIP–chip analysis enables careful comparison between the patterns of BCL11A occupancy and other transcriptional marks, such as common histone modifications. These comparisons reveal that BCL11A-binding sites are generally excluded from activating histone marks, such as acetylated histone H3 and di- and trimethylated H3K4 (Fig. 1A). Specifically, the BCL11A-binding peaks at the upstream HS3 site within the LCR and the intergenic regions between Αγ-globin and δ-globin genes are located in the “valley” of peaks for active histone modifications (Fig. 1A). No detectable peaks of trimethylated H3K27, a mark generally associated with transcription repression, are observed at the above binding sites for BCL11A (Fig. 1A). The three strong BCL1A peaks at the ε-globin are also devoid of any histone modifications. Genome-wide analyses also reveal a similar lack of co-occupancy between BCL11A and common histone modifications (Fig. 1E; Supplemental Fig. 2). The pattern of chromatin occupancy for BCL11A is distinct from that of other transcription factors such as GATA1 and SOX6, as we and others have shown (Fig. 5; Cheng et al. 2009; Yu et al. 2009). Several possibilities may account for the lack of common histone modifications at BCL11A-binding sites. BCL11A and/or associated protein partners, once bound to their target regions, may protect the nucleosomes at their binding sites from histone-modifying enzymes. BCL11A-binding sites may bear specific chromatin features that make them inaccessible to histone-modifying enzymes. Alternatively, BCL11A may tend to bind to nucleosome-free regions. Nevertheless, this special feature of BCL11A chromatin occupancy may be essential for its action in repressing gene expression by modulating long-range interactions (Fig. 2).

Over the past years, various models for the molecular control of globin switching have been put forward. These include autonomous gene silencing, gene competition, chromosomal looping, and tracking (Orkin 1990; Stamatoyannopoulos 2005; Bank 2006). The “chromosomal looping” model assumes flexibility of the chromatin fiber and predicts that distal control elements and inactive genes loop out, may protect the nucleosomes at their binding sites from histone-modifying enzymes. Moreover, it is likely that each model oversimplifies what occurs in an actual erythroid progenitor during globin gene expression. For example, while strong evidence supports intrachromosomal looping of the upstream LCR to the downstream genes within the β-globin locus, looping by itself does not preclude transient tracking within the locus or autonomous gene silencing of individual globin genes (Tolhuis et al. 2002; Palstra et al. 2003; Yakoc et al. 2005; Sankaran et al. 2010). The findings we describe here argue strongly that multiple modes of action may be employed by BCL11A in controlling hemoglobin switching, as well as silencing of γ-globin genes. BCL11A binds to distal control regions (the upstream LCR and the γδ-intergenic sites) and reconfigures the architecture of the β-globin cluster by chromosomal looping (Fig. 2). In the presence of BCL11A, the upstream LCR and downstream 3′HS1 interact preferentially with the transcriptionally active adult (β-globin) gene in adult-type erythroid cells. In the absence of BCL11A, the intrachromosomal looping within the β-globin cluster is reconfigured such that the LCR and 3′HS1 strongly favor interaction with the fetal (γ-globin) genes (Fig. 2). Importantly, BCL11A may also silence γ-globin expression by local interactions with the chromatin-associated SOX6 proteins at the proximal promoters of the γ-globin genes, as discussed below. Therefore, the function of BCL11A in controlling hemoglobin switching and γ-globin silencing not only reflects the complexity of transcriptional regulation occurring at the human β-globin locus, but provides new insight into further dissection of the globin switching process for targeted reactivation of Hbf in patients with β-hemoglobin diseases.

In the present study, we also show that SOX6 is coexpressed with BCL11A during erythroid development, interacts physically with BCL11A and GATA1, and cooccupies the human β-globin cluster in vivo. Moreover, depleting the expression of both SOX6 and BCL11A leads to substantial derepression of mouse embryonic β-like globins in MEL cells and reactivation of γ-globins in adult human erythroid precursors. These results suggest that involvement of both BCL11A and SOX6 is preserved during mammalian evolution; however, their exact roles in cellular function, such as silencing of the embryonic or Hbf expression, can be divergent. Our findings also illustrate that some evolutionarily conserved trans-acting factors may perform divergent regulatory functions among different species.

While the precise role of SOX6 in repressing mouse embryonic β-like globins and human γ-globins merits further study, SOX6 can act as either an activator or a repressor, depending on its interacting proteins and promoter context (Lefebvre et al. 1998; Murakami et al. 2001). SOX6 contains an evolutionarily conserved HMG domain that is essential for its DNA-binding activity (Grosschedl et al. 1994). HMG domain factors are capable of binding to the minor groove of the DNA and four-way junctions, and induce drastic DNA bending on binding
BCL11A mediates silencing of \( g \)-globin genes through mediation of globin switching and silencing of repressor complexes to the proximity of BCL11A and SOX6 (Supplemental Fig. 7). The physical interaction between BCL11A, GATA1, and FOG1, but not the NuRD components MTA2 and MBD3 (Fig. 4B–G; Supplemental Fig. 7). The physical interaction between BCL11A and SOX6 may help recruit BCL11A and NuRD to assembled genes by bridging other distant regions of DNA and associated factors and facilitating the assembly of high-order complexes (Thomas 2001). Specifically, HMG transcription factors (HMGs) have been suggested to modulate the \( g \)-globin genes (Dyer et al. 1996, 1998; Bagga et al. 2000; Drew et al. 2000).

Using a proteomic approach, we demonstrated previously that BCL11A interacts with the NuRD chromatin remodeling and repressor complex, the erythroid transcription factors GATA1 and FOG1, and the nuclear matrix component Matrin-3 in erythroid progenitors (Sankaran et al. 2008). In this study, we show that SOX6 interacts with BCL11A, GATA1, and FOG1, but not the NuRD components MTA2 and MBD3 (Fig. 4B–G; Supplemental Fig. 7). The physical interaction between BCL11A and SOX6 may help recruit BCL11A and NuRD repressor complexes to the proximity of \( g \)-globin genes. Thus, SOX6 may act as an important cofactor of BCL11A in mediating globin switching and silencing of \( g \)-globin transcription. Our results suggest a model in which BCL11A mediates silencing of \( g \)-globin genes through both long-range interaction within the human \( g \)-globin cluster and local interactions with the chromatin-associated SOX6 proteins at the proximal promoters of the \( g \)-globin genes (Fig. 7). In summary, these findings provide critical insights into the mechanism of BCL11A action, and identify a second factor required for effective \( g \)-globin silencing. An in-depth understanding of the role for BCL11A and its interacting proteins in globin switching offers the prospect for the design of target-based activation of \( HbF \) in adult erythroid cells of patients with hemoglobin disorders.

Figure 7. Model of BCL11A-mediated silencing of \( g \)-globin genes. The diagram illustrates the physical interaction between BCL11A and the Mi-2/NuRD complexes, erythroid transcription factors GATA1 and FOG1, and the HMG-box protein SOX6. Rather than binding to the promoters of the \( g \)-globin or \( \beta \)-globin genes as these latter factors do, BCL11A protein occupies the upstream LCR and \( \gamma \)-intergenic regions of the \( \beta \)-globin cluster in adult human erythroid progenitors. Our study suggests that transcriptional silencing of \( g \)-globin expression by BCL11A involves long-range interaction within the \( \beta \)-globin cluster and local interactions with the chromatin-associated SOX6 proteins at the proximal promoters of the \( g \)-globin genes.

Materials and methods

Cell culture and transfection

Primary human CD34+ cells were obtained from Yale Center of Excellence in Molecular Hematology (YCEMH). CD34+ cells were prepared from magnetically sorted mononuclear samples of G-CSF mobilized peripheral blood from donors. Cells were cultured initially for expansion in StemSpan SFEM Medium (StemCell Technologies, Inc.) supplied with 1× CC100 cytokine mix (StemCell Technologies, Inc.) and 2% penicillin-streptomycin (P/S) for 6 d. Cells were maintained at a density of 0.1×10^6 to 1×10^6 cells per milliliter with media changes every other day. On day 6, cells were pelleted and transferred into StemSpan SFEM Medium with 2% P/S, ethyrosperoitin [1 U/mL], IL-3 [5 mg/mL], SCF [20 ng/mL], dexamethasone (2 \( \mu \)M), and \( \beta \)-estradiol (1 \( \mu \)M). Cells were incubated at 37°C with 5% CO\(_2\) and maintained at a density of 0.1×10^6 to 1×10^6 cells per milliliter by supplementing cultures every other day with fresh media. COS-7 and MEL cells were maintained in DMEM with 10% FCS. COS7 cells were transfected with the FuGene 6 (Roche) reagent according to the manufacturer’s instructions. Lin− (excluding the Ter119 antibody) CD17+Ter119− cells were FAC-sorted from E14.5 mouse fetal liver cells as described previously (Sankaran et al. 2008).

Experimental animals

The wild-type \( \beta \)-globin locus YAC transgenic (\( \beta \)-YAC) mice (Porcu et al. 1997; Peterson et al. 1998) were crossed with mice containing a Bcl11a floxed allele (Sankaran et al. 2009). To obtain Bcl11a-null \( \beta \)-YAC mice, these mice were crossed with Gata1-Cre mice and screened for germline deletions (Jasinski et al. 2001). All experiments were performed with the approval of the Children’s Hospital Boston Animal Ethics Committee.

Antibodies and reagents

Antibodies against GATA1 (sc-265), HDAC2 (sc-7899), MBD3 (sc-9402), Pol II (sc-899), GAPDH (sc-25778), normal rabbit IgG (sc-2025) and normal mouse IgG (sc-9402), Pol II (sc-899), GAPDH (sc-25778), normal rabbit IgG (sc-2025) were purchased from Santa Cruz Biotechnologies. BCL11A (ab1: 15E3AC11; ab2: 1485), SOX6 (ab64946), and GATA1 (ab47490) antibodies were purchased from Abcam. SOX6 (NP1P1-19837) and BCL11A (ab5: NP600-261) antibodies were purchased from Novus Biologicals, LLC. HDAC1 antibody (06-720) was purchased from Upstate Biotechnologies. \( \beta \)-Actin antibody (MAB1501R) was purchased from Chemicon. SOX6 antibodies (αSox6C and αSox6N) were kindly provided by Dr. Paolo Sassone-Corsi (University of California at Irvine).

RNA isolation and RT–PCR

RNA was isolated using the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s protocol. cDNA was synthesized with the iScript cDNA synthesis kit (Bio-Rad). Real-time quantitative RT–PCR was performed using the iQ SYBR Green Supermix (Bio-Rad). Relative expression was quantified using the \( \Delta \Delta Ct \) method as described previously (Xu et al. 2009). Sequences of primers are available on request.

Co-IP and Western blot

For endogenous co-IP experiments, 1–5 mg of nuclear extract protein were treated with DNase1 (1 μg/mL), RNase A (1 μg/mL), and ethidium bromide (50 μg/mL), and incubated with 25 μg...
of BCL11A or SOX6 antibody on a rotating wheel overnight at 4°C. The protein complexes were collected by addition of protein G/A-agarose beads (Roche), followed by incubation for 3 h at 4°C. The beads were washed four times in BC139K for 15 min and then boiled for 5 min in sample buffer [Bio-Rad]. Eluted material was used for Western blot analysis. For interaction mapping studies, COS-7 cells were transiently cotransfected with 5 × 10^7 to 10^8 cells per well of B-cl and the mouse m b-globin locus (Yu et al. 2009). Briefly, 0.5 ChIP was performed as described previously with slight modifications. Green Supermix (Bio-Rad) was used for quantitative real-time PCR using the iQ SYBR Green kit. DNA ligation was performed for 10 min with ice-cold lysis buffer (10 mM Tris-HCl at pH 8.0, 10 mM NaCl, 0.2% NP-40, 1 mM dithiothreitol). The nuclei were harvested and resuspended in appropriate restriction enzyme buffer containing 0.3% SDS and incubated for 1 h at 37°C with vigorous shaking. Triton X-100 was added to 2% to sequester the SDS, and samples were incubated for another 1 h at 37°C. Samples were digested with EcoRI overnight at 37°C. DNA ligation was performed for 4.5 h at 16°C and 30 min at room temperature. Cross-links were reversed, and DNA was then purified by phenol extraction and ethanol precipitation. All PCR products were amplified, cloned, and verified by DNA sequencing. To compare the cross-linking frequency and ligation efficiency between two restriction fragments present on an unrelated locus, PCR reactions were normalized to Ercc3 locus [Palstra et al. 2003]. To correct for the PCR amplification efficiency of different primer sets, a BAC clone spanning the complete human b-globin locus (CTD-3055E11) and a BAC clone containing the mouse Ercc3 locus (RP24-97P16) were used as control templates. Equimolar amounts of human b-globin BAC and the mouse Ercc3 BAC were mixed, digested, and ligated. Quantitation of the data was performed by quantitative real-time PCR using the iQ SYBR Green Supermix [Bio-Rad].

**ChIP and ChIP–chip**

ChIP was performed as described previously with slight modifications (Yu et al. 2009). Briefly, 0.5 × 10^7 to 1 × 10^7 cells per immunoprecipitation were cross-linked with 1% formaldehyde for 10 min at room temperature. Chromatin was sonicated in RIPA buffer with 0.3 M NaCl to ~500 bp. Dynabeads Protein A or G [Invitrogen] was used for collection of chromatin. For GATA1 ChIP, beads were incubated with rabbit anti-rat IgG [H + L] [Jackson Research Laboratories, Inc.] before incubation with the primary antibody. Antibodies were incubated with beads for 3 h before incubating with sonicated chromatin overnight. ChIP DNA was quantified by real-time PCR using the iQ SYBR Green Supermix [Bio-Rad]. ChIP–chip experiments were performed using Affymetrix human ENCODE 2.0R array comprised of 30 Mb of DNA, or ~1% of the human genome [http://www.ncbi.nlm.nih.gov/1005107] as described previously [Lupien et al. 2008]. For each ChIP–chip experiment, two to three independent assays were performed. Model-based analysis of tiling array [MAT] (Johnson et al. 2006) was used to predict and map significant peaks (P < 1e-3) to the genome based on the human hg17 genome assembly. Genomic distribution of binding sites identified by ChIP–chip was performed using cis-regulatory element annotation system [CEAS] [Ji et al. 2006; Shin et al. 2009]. Two binding sites were considered to overlap if they had at least 1 bp in common. The average size of ChIP–chip regions is ~1 kb, which means that the center of the two binding sites had to be, on average, within 1 kb of each other to be considered overlapping.

**Lentiviral RNAi**

Lentiviral shRNA constructs in the pLKO vector were obtained from a large collection of shRNAs as described previously [Moffat et al. 2006; Sankaran et al. 2008]. shRNA targeting human BCL11A gene contains the sequence CCGGGCGCACAG AACACTCTAGATCAGAAGTTGCAGTCTCTTGTGCTGTG CTGTTTTTG, shRNA targeting human SOX6 gene contains the sequence CCGGGCGCACAG AACACTCTAGATCAGAAGTTGCAGTCTCTTGTGCTGTG CTGTTTTTG, shRNA targeting mouse Bcl11a gene contains the sequence CCGGGGCATAGCAGTGTC ACTGTATCTCAGAAGTTGCAGTCTCTTGTGCTGTG CTGTTTTTG, and shRNA targeting mouse Sox6 gene contains the sequence CCGGGGCATAGCAGTGTC ACTGTATCTCAGAAGTTGCAGTCTCTTGTGCTGTG CTGTTTTTG. The empty vector pLKO.1ps was used to produce control lentiviruses. Lentiviruses were prepared and transduction of cells was carried out as described [Moffat et al. 2006]. The cells were washed three times with PBS and seeded in fresh media 24 h post-transduction. Selection with puromycin was initiated at 48 h post-transduction, which generally corresponded to the time when the cells were seeded into differentiation medium. To knock down both BCL11A and SOX6, cells were transduced with lentiviruses containing SOX6 shRNA (in pLKO vector with puromycin-selectable marker) and BCL11A shRNA (in pLKO vector with GFP). Cells were selected with puromycin as described above. GFP-positive cells were FACS-sorted on the day of harvest.

**Hemoglobin analysis**

Hemolysates were prepared from cells (2 × 10^7 to 3 × 10^7) on days 12–15 of the differentiation phase of erythroid culture. Cells were lysed in 100 μL of hemolyse reagent [Helena Laboratories], and refrigerated overnight before centrifuging at 14,000 rpm for 10 min at 4°C to remove cellular debris. The cleared supernatant was used for characterization of hemoglobin production by cellulose acetate hemoglobin electrophoresis or HPLC as described previously (Sankaran et al. 2008).

**Acknowledgments**

We are grateful to P. Sassone-Corsi for providing α-SOX6 antibodies. We thank members of the Orkin laboratory for technical assistance and comments. We thank M. Lupien, H. He, S. Baily, X.S. Liu, M.H. Brilliant, and N. Hagiwara for helpful advice and discussions. This work was supported by funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute [NHLBI] of the National Institutes of Health [NIH] to S.H.O. S.H.O. is an Investigator of the Howard Hughes Medical Institute [HHMI]. T.F.M. is supported by the Kay Kendall Leukaemia Fund.

Transcriptional silencing of γ-globin by BCL11A
References


Lefebvre V, Li P, de Crombrugghe B. 1998. A new long form of Sox5 [L-Sox5], Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. *EMBO J* 17: 5718–5733.


